GlobeNewswire Inc.··NaBoehringer Ingelheim, Zai Lab Partner on DLL3 Combo Therapy for Lung Cancer
Boehringer Ingelheim and Zai Lab collaborate on Phase Ib/II study combining T-cell engager obrixtamig with ADC zocilurtatug for small cell lung cancer treatment.
ZLABADC (antibody drug conjugate)immuno-oncology